We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

69 hedge funds and large institutions have $226M invested in Biotech Acquisition Company Class A Ordinary Shares in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 9

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

3% more funds holding

Funds holding: 67 → 69 (+2)

4% more capital invested

Capital invested by funds: $218M → $226M (+$7.64M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
69
Holders Change
+2
Holders Change %
+2.99%
% of All Funds
1.19%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
9
Increased
15
Reduced
9
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
+$16.3M
2
HSBC Holdings
HSBC Holdings
United Kingdom
+$6.31M
3
MSU
Mizuho Securities USA
New York
+$4.4M
4
Millennium Management
Millennium Management
New York
+$2.45M
5
WRBC
W.R. Berkley Corp
Connecticut
+$2.36M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$18M
2
LA
Linden Advisors
New York
-$6.31M
3
RL
RPO LLC
Connecticut
-$2.47M
4
WAM
Weiss Asset Management
Massachusetts
-$2.33M
5
Goldman Sachs
Goldman Sachs
New York
-$2.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
26
Sculptor Capital
New York
$2.98M +$2.94K +298 +0.1%
ACA
27
Arena Capital Advisors
California
$2.98M – – –
CH
28
CVI Holdings
Delaware
$2.9M – – –
WRBC
29
W.R. Berkley Corp
Connecticut
$2.86M +$2.36M +239,155 +487%
WAM
30
Wolverine Asset Management
Illinois
$2.49M – – –
Deutsche Bank
31
Deutsche Bank
Germany
$2.48M – – –
OAC
32
OMERS Administration Corp
Ontario, Canada
$2.45M – – –
RCM
33
Rivernorth Capital Management
Florida
$2.2M – – –
JP Morgan Chase
34
JP Morgan Chase
New York
$1.99M -$18M -1,816,756 -90%
BFM
35
Boothbay Fund Management
New York
$1.94M -$1.27M -128,569 -40%
CCM
36
Context Capital Management
California
$1.93M +$1.92M +194,400 New
PMAM
37
Picton Mahoney Asset Management
Ontario, Canada
$1.49M – – –
Jane Street
38
Jane Street
New York
$1.44M -$1.53M -154,578 -52%
Citadel Advisors
39
Citadel Advisors
Florida
$1.44M -$15.7K -1,589 -1%
TCM
40
Tenor Capital Management
New York
$1.43M – – –
Walleye Capital
41
Walleye Capital
New York
$1.17M – – –
CSS
42
Cubist Systematic Strategies
Connecticut
$1.14M +$964K +97,515 +547%
SCM
43
Shaolin Capital Management
Florida
$1.06M – – –
LP
44
LMR Partners
United Kingdom
$992K – – –
HF
45
HRT Financial
New York
$917K +$484 +49 +0.1%
Janus Henderson Group
46
Janus Henderson Group
United Kingdom
$828K +$412K +41,715 +100%
Walleye Trading
47
Walleye Trading
New York
$788K – – –
SSA
48
Schonfeld Strategic Advisors
New York
$729K +$577K +58,400 +388%
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
$600K +$597K +60,459 New
YCM
50
Yakira Capital Management
Connecticut
$534K – – –
1
2
3 4

BIOT Hedge Fund Activity: Q3 2022 in Review

69 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q3 2022, worth a combined $226M — up 3.5% from $218M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new BIOT positions and 7 closed out — a net gain of 2 holders — while 15 added to existing stakes and 9 trimmed.

The largest buyer was Glazer Capital LLC, adding an estimated $16.3M. The largest seller was JP Morgan Chase, cutting an estimated $18M.

  • 69 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q3 2022, up from 67 in Q2 2022.
  • Funds reported $226M of Biotech Acquisition Company Class A Ordinary Shares stock for Q3 2022, up 3.5% quarter-over-quarter.
  • 9 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q3 2022 and 7 closed out, a net change of +2 holders.
  • The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q3 2022 was Glazer Capital LLC, an estimated $16.3M added.
  • The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q3 2022 was JP Morgan Chase, an estimated $18M sold.

Based on aggregated 13F filings for Q3 2022.